Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWX9 | ISIN: US87583X1090 | Ticker-Symbol:
NASDAQ
21.05.24
22:15 Uhr
7,470 US-Dollar
-0,200
-2,61 %
1-Jahres-Chart
TANGO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TANGO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TANGO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.05.Tango Therapeutics Q1 GAAP EPS of -$0.35 misses by $0.041
08.05.Tango Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.Tango Therapeutics, Inc. - 8-K, Current Report1
08.05.Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights63BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines...
► Artikel lesen
18.03.Recap: Tango Therapeutics Q4 Earnings1
18.03.Tango Therapeutics Inc reports results for the quarter ended in December - Earnings Summary2
18.03.Tango Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Tango Therapeutics, Inc. Q4 Loss misses estimates1
18.03.Tango Therapeutics, Inc. - 10-K, Annual Report1
18.03.Tango Therapeutics GAAP EPS of -$0.32 misses by $0.04, revenue of $5.43M misses by $2.81M1
18.03.Tango Therapeutics, Inc. - 8-K, Current Report1
18.03.Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights133BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines...
► Artikel lesen
05.03.Tango Therapeutics, Inc.: Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 202441BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
► Artikel lesen
12.02.Piper Sandler starts Tango Therapeutics Shares with Overweight1
07.02.Tango Therapeutics, Inc. - 8-K, Current Report-
31.01.Tango Therapeutics, Inc.: Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference1
05.01.Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)164BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
► Artikel lesen
04.01.Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study195STOCKHOLM, Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
13.11.23Tango Therapeutics, Inc.: Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting349- Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers - BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics...
► Artikel lesen
29.08.23Tango Therapeutics, Inc.: Tango Therapeutics Announces Updates to Its Board of Directors404BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1